{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:26:10Z","timestamp":1780388770011,"version":"3.54.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T00:00:00Z","timestamp":1348704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Splenic marginal zone lymphoma (<jats:styled-content style=\"fixed-case\">SMZL<\/jats:styled-content>) is a rare B\u2010cell malignancy, with no standard treatment other than splenectomy. Rituximab has shown encouraging results. We therefore retrospectively assessed 43 patients from two centres, who received rituximab, either alone or with chemotherapy. All patients responded, 34\/43 (79%) achieving a complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>), compared with 3\/10 (30%) after chemotherapy without rituximab (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7005). Of these 10 patients, 9 (90%) subsequently achieved a <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> after rituximab (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b702). Rituximab monotherapy appeared equally as effective as rituximab combination therapy (90% vs. 79% <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>,<jats:italic> P<\/jats:italic>\u00a0=\u00a00\u00b77) with significantly less toxicity (12\u00b75% vs. 83%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7002). Splenectomized patients were more likely to obtain a <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> with rituximab (16\/16, 100%) than unsplenectomized patients (18\/27, 67%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7008). Disease\u2010free survival (<jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content>) at 3\u00a0years was better after rituximab than after splenectomy alone [79% (95% confidence interval 60\u201389) vs. 29% (8\u201354), Hazard ratio (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>) 0\u00b728 (0\u00b712\u20130\u00b768), <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7003] and better than after chemotherapy without rituximab [25% (4\u201355), <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0\u00b721 (0\u00b708\u20130\u00b751), <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b70004]. Survival at 3\u00a0years after rituximab was 98%. In summary, the <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content> rates after rituximab, given alone or with chemotherapy, were significantly better than after chemotherapy without rituximab in the same patients, with manageable toxicity. Rituximab, with or without splenectomy, should be considered for the treatment of <jats:styled-content style=\"fixed-case\">SMZL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12036","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T03:02:43Z","timestamp":1348801363000},"page":"322-328","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma"],"prefix":"10.1111","volume":"159","author":[{"given":"Monica","family":"Else","sequence":"first","affiliation":[{"name":"Royal Marsden Hospital and the Institute of Cancer Research Sutton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mar\u00edn\u2010Niebla","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and the Institute of Cancer Research Sutton UK"},{"name":"Hospital Virgen del Roc\u00edo Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"de la Cruz","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Batty","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and the Institute of Cancer Research Sutton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"R\u00edos","sequence":"additional","affiliation":[{"name":"Hospital Nuestra Se\u00f1ora de Valme Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Dearden","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and the Institute of Cancer Research Sutton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Catovsky","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and the Institute of Cancer Research Sutton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estella","family":"Matutes","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and the Institute of Cancer Research Sutton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.005"},{"key":"e_1_2_8_3_1","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett M.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07677.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07301.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.568650"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.033"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_8_9_1","first-page":"185","volume-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"Isaacson P.G.","year":"2008"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0032-2"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.820"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403440"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-007-0026-0"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405068"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04165.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"e_1_2_8_17_1","first-page":"CD003805","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B\u2010cell non\u2010Hodgkin's lymphoma","volume":"17","author":"Schulz H.","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-14"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00981-1"},{"issue":"1","key":"e_1_2_8_20_1","first-page":"134a","article-title":"Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab","volume":"98","author":"Thomas D.A.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21931"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr418"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1811"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12036","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T07:04:10Z","timestamp":1700550250000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/bjh.12036"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12036","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,27]]},"assertion":[{"value":"2012-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}